Email: ir@altimmune.com
Search
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
December 19, 2025 - … (ALD). For more information, please visit www.altimmune.com . Forward-Looking Statement Any statements made in this … Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Savannah Valade Real Chemistry Altimmune@realchemistry.com Source: Altimmune, Inc Improvements observed in key …
Altimmune Announces CEO Transition and Succession Plan
December 1, 2025 - … (ALD). For more information, please visit www.altimmune.com . Forward-Looking Statements Any statements made in this … Investor Contact: Lee Roth Burns McClellan lroth@burnsmc.com Media Contact: Savannah Valade Real Chemistry altimmune@realchemistry.com Source: Altimmune, Inc Jerry Durso , accomplished …
Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025
November 11, 2025 - … (ALD). For more information, please visit www.altimmune.com . Forward-Looking Statements Any statements made in this … Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Savannah Valade Real Chemistry altimmune@realchemistry.com This press release was published by a CLEAR® Verified …
Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025
November 7, 2025 - … (ALD). For more information, please visit www.altimmune.com . Forward Looking Statements Any statements made in this … Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Savannah Valade Real Chemistry altimmune@realchemistry.com This press release was published by a CLEAR® Verified …
Altimmune Announces Third Quarter 2025 Financial Results and Business Updates
November 6, 2025 - … Investor Relations website at https://ir.altimmune.com/investors . Dial-in: To participate or dial-in, register … (IR) page of the Company’s website at www.altimmune.com . The Company has used, and intends to continue to use, … (ALD). For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow …
Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder
November 3, 2025 - … (ALD). For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Elliot Fox Real Chemistry efox@realchemistry.com This press release was published by a CLEAR® Verified …
Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide
September 29, 2025 - … obesity. For more information, please visit www.altimmune.com . Forward-Looking Statements Any statements made in this … Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Source: Altimmune, Inc Seasoned clinical leader to … obesity. For more information, please visit www.altimmune.com . Forward-Looking Statements Any statements made in this …
Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer
September 15, 2025 - … obesity. For more information, please visit www.altimmune.com . Forward-Looking Statements Any statements made in this … Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jake Robison Inizio Evoke Comms Phone: …
Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)
August 19, 2025 - … obesity. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow … Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Jake Robison Inizio Evoke Comms Phone: …
Altimmune Announces Second Quarter 2025 Financial Results and Business Update
August 12, 2025 - … Investor Relations website at https://ir.altimmune.com/investors . Dial-in: To participate or dial-in, register … (IR) page of the Company’s website at www.altimmune.com . The Company has used, and intends to continue to use, … obesity. For more information, please visit www.altimmune.com . Follow @Altimmune, Inc. on LinkedIn Follow …
